AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $51,000.00 income · posted Jan 15, 2026

Lobbying activity 1

Health Issues

FAIR Act FDA Modernization

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem